Literature DB >> 17994572

The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases.

Nee K Chew1, Pablo Mir, Mark J Edwards, Carla Cordivari, Davide Martino, Susanne A Schneider, Hee-Tae Kim, Niall P Quinn, Kailash P Bhatia.   

Abstract

We report eight cases of genetically proven ULD, with the aim of reassessing the clinical characteristics and natural history of ULD in genetically characterized patients. The eight patients had their first symptoms at mean age of 10.6 years (range: 6-14 years). The main clinical features were action myoclonus, cerebellar ataxia, seizures, and mild intellectual dysfunction. We report three new clinical features of ULD; ocular motor apraxia, dystonia, and rapidly progressive dementia. All patients needed a combination of at least four antimyoclonic drugs, but despite this, all patients were severely disabled by their action myoclonus. After a mean duration of disease of 29.9 years (range: 21-37 years), four patients were walking with aids while another four were wheelchair bound. The clinical phenotypes associated with ULD are more diverse than previously recognized and even though the long term functional outcome and survival have improved, the overall efficacy of antimyoclonic drugs remains unsatisfactory. 2007 Movement Disorder Society

Entities:  

Mesh:

Year:  2008        PMID: 17994572     DOI: 10.1002/mds.21812

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

1.  A new, progressive myoclonic epilepsy: is it a chronicle of the noncanonical or a failure to REST?

Authors:  Martin Gallagher
Journal:  Epilepsy Curr       Date:  2009 May-Jun       Impact factor: 7.500

2.  Sensorimotor, visual, and auditory cortical atrophy in Unverricht-Lundborg disease mapped with cortical thickness analysis.

Authors:  P Koskenkorva; E Niskanen; J Hyppönen; M Könönen; E Mervaala; H Soininen; R Kälviäinen; R Vanninen
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

Review 3.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

4.  FDG-PET findings and alcohol-responsive myoclonus in a patient with Unverricht-Lundborg disease.

Authors:  Lorenzo Muccioli; Andrea Farolfi; Federica Pondrelli; Eleonora Matteo; Lorenzo Ferri; Laura Licchetta; Lara Alvisi; Paolo Tinuper; Francesca Bisulli
Journal:  Epilepsy Behav Rep       Date:  2022-05-13

5.  Progressive myoclonic epilepsy type 1: Report of an Emirati family and literature review.

Authors:  Mohammed Saadah; Mahfoud El Beshari; Loai Saadah; Hisham Hamdallah; Zeinab Alloub; Amani Ali Al Zaabi; Abdelmatlob Ben-Mussa; Anwaar Ben-Nour
Journal:  Epilepsy Behav Case Rep       Date:  2014-05-04

6.  Progressive volume loss and white matter degeneration in cstb-deficient mice: a diffusion tensor and longitudinal volumetry MRI study.

Authors:  Otto Manninen; Teemu Laitinen; Kimmo K Lehtimäki; Saara Tegelberg; Anna-Elina Lehesjoki; Olli Gröhn; Outi Kopra
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

Review 7.  Cognitive Dysfunction in Repeat Expansion Diseases: A Review.

Authors:  Sizhe Zhang; Lu Shen; Bin Jiao
Journal:  Front Aging Neurosci       Date:  2022-04-11       Impact factor: 5.750

8.  3D texture analysis reveals imperceptible MRI textural alterations in the thalamus and putamen in progressive myoclonic epilepsy type 1, EPM1.

Authors:  Sanna Suoranta; Kirsi Holli-Helenius; Päivi Koskenkorva; Eini Niskanen; Mervi Könönen; Marja Äikiä; Hannu Eskola; Reetta Kälviäinen; Ritva Vanninen
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.